REPRISE II Data Honored as Best Abstract 2013 at PCR London Valves Course Boston Scientific Corporation (NYSE: BSX) reported favorable six-month results from the first 60 patients enrolled in the...

In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY™ Stent System, Boston Scientific Corporation (NYSE: BSX) has completed enrollment in the EVOLVE II...

A breakthrough Boston Scientific technology for the treatment of severe asthma has been shown to be safe and effective over at least five years, according to data published online in a key medical...

First Patient Treated in OPTIMISE Clinical Trial Evaluating Safety, Efficacy of Occipital Nerve Stimulation Using Precision™ System Boston Scientific Corporation (NYSE: BSX) has launched a...

In a move that would significantly boost its capabilities in the fast-growing market for advanced electrophysiology procedures, Boston Scientific Corporation (NYSE:BSX) has entered into a...

The first patient implant of the Boston Scientific Corporation (NYSE: BSX) VITALIO™ pacemaker was performed at ZGT Hengelo in Hengelo, the Netherlands. In addition to a comprehensive suite of...

Boston Scientific Corporation (NYSE: BSX) is launching a new family of pacemakers in Europe. These pacemakers monitor respiration, adjust pacing accordingly, and support insight into the patient?s...

The Boston Scientific Corporation (NYSE:BSX) S-ICD® (subcutaneous implantable defibrillator) System showed a significant reduction in major lead-related complications when compared with both...

Boston Scientific Corporation (NYSE: BSX) reports positive results from two trials evaluating new, innovative drug-eluting stent (DES) technologies, which are emerging treatment options for...

Boston Scientific Corporation (NYSE: BSX) reports positive results from a pre-specified analysis of the first 60 patients enrolled in the REPRISE II trial evaluating the performance and safety of...